Video

From Landmark Trials to Evidence-Based Therapy for Resistant, Refractory, High Risk and/or Challenging Patients with MAC Lung Infection

Name: From Landmark Trials to Evidence-Based Therapy for Resistant, Refractory, High Risk and/or Challenging Patients with MAC Lung Infection
Uploaded: 2021-08-27T00:00:00+00:00
Description: The Role, Safety, Indications, Evidence, and Efficacy of Novel, Inhaled Antimicrobial Formulations

Error loading media: File could not be played

00:0000:0000:00

00:00

From Landmark Trials to Evidence-Based Therapy for Resistant, Refractory, High Risk and/or Challenging Patients with MAC Lung Infection

Continue to Test Back to Symposium

The Role, Safety, Indications, Evidence, and Efficacy of Novel, Inhaled Antimicrobial Formulations

Published

August 27, 2021

Created by

Related Presenters

Rachel Thomson, MD

Director, Mycobacterial Diseases
Gallipoli Medical Research Institute
University of Queensland
Brisbane, QLD, Australia